DK14587D0 - Anvendelse af specifikke n-methyl-d-aspartat-receptorantagonister til undgaaelse af og behandling af neurodegeneration - Google Patents

Anvendelse af specifikke n-methyl-d-aspartat-receptorantagonister til undgaaelse af og behandling af neurodegeneration

Info

Publication number
DK14587D0
DK14587D0 DK014587A DK14587A DK14587D0 DK 14587 D0 DK14587 D0 DK 14587D0 DK 014587 A DK014587 A DK 014587A DK 14587 A DK14587 A DK 14587A DK 14587 D0 DK14587 D0 DK 14587D0
Authority
DK
Denmark
Prior art keywords
treat
methyl
avoid
specific
application
Prior art date
Application number
DK014587A
Other languages
English (en)
Other versions
DK170921B1 (da
DK14587A (da
Inventor
Geoffrey Neil Woodruff
Erik Ho Fong Wong
John Alan Kemp
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of DK14587D0 publication Critical patent/DK14587D0/da
Publication of DK14587A publication Critical patent/DK14587A/da
Application granted granted Critical
Publication of DK170921B1 publication Critical patent/DK170921B1/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK014587A 1986-01-14 1987-01-13 Anvendelse af forbindelser til fremstilling af et farmaceutisk præparat med NMDA-receptorantagonistisk virkning DK170921B1 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB868600783A GB8600783D0 (en) 1986-01-14 1986-01-14 N-methyl-d-aspartate receptor antagonists
GB8600783 1986-01-14

Publications (3)

Publication Number Publication Date
DK14587D0 true DK14587D0 (da) 1987-01-13
DK14587A DK14587A (da) 1987-07-15
DK170921B1 DK170921B1 (da) 1996-03-18

Family

ID=10591339

Family Applications (1)

Application Number Title Priority Date Filing Date
DK014587A DK170921B1 (da) 1986-01-14 1987-01-13 Anvendelse af forbindelser til fremstilling af et farmaceutisk præparat med NMDA-receptorantagonistisk virkning

Country Status (8)

Country Link
US (1) US4888347A (da)
EP (1) EP0230370B1 (da)
JP (1) JP2549643B2 (da)
CA (1) CA1284952C (da)
DE (1) DE3780972T2 (da)
DK (1) DK170921B1 (da)
GB (1) GB8600783D0 (da)
IL (1) IL81162A (da)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4806543A (en) * 1986-11-25 1989-02-21 Board Of Trustees Of The Leland Stanford Junior University Method and compositions for reducing neurotoxic injury
GB8719199D0 (en) * 1987-08-13 1987-09-23 Merck Sharp & Dohme Chemical compounds
GB8727989D0 (en) * 1987-11-30 1988-01-06 Merck Sharp & Dohme Therapeutic agents
DE3839659A1 (de) * 1988-11-24 1990-05-31 Boehringer Ingelheim Kg Verwendung von benzomorphanen zur zytoprotektion
US5399572A (en) * 1989-02-17 1995-03-21 Aktiebolaget Astra Chlormethiazole in the treatment of neurodegeneration
US5011834A (en) * 1989-04-14 1991-04-30 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University And The University Of Oregon PCP receptor ligands and the use thereof
US5688789A (en) * 1989-04-14 1997-11-18 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University And The University Of Oregon PCP receptor ligands and the use thereof
JP2899062B2 (ja) * 1989-09-28 1999-06-02 協和醗酵工業株式会社 化合物ｅｓ―２４２
EP0424179A3 (en) * 1989-10-20 1991-12-27 John William Olney Use of combined excitatory amino acid and cholinergic antagonists to prevent neurological deterioration
US5474990A (en) * 1989-10-20 1995-12-12 Olney; John W. Barbiturates as safening agents in conjunction with NMDA antagonists
US5229394A (en) * 1990-07-30 1993-07-20 Arch Development Corporation Method for treatment of amyotrophic lateral sclerosis comprising administration of dmp
SE9002659D0 (sv) 1990-08-15 1990-08-15 Astra Ab New pharmaceutical formulations
US5064831A (en) * 1990-09-14 1991-11-12 Bristol-Myers Squibb Co. Naphthothiophenimines for treating neuronal disorders caused by ischemia
US5141934A (en) * 1990-10-30 1992-08-25 Warner-Lambert Company Tetracyclic amines having pharmaceutical activity
US5118675A (en) * 1991-02-15 1992-06-02 American Home Products Corporation Quinoxaline phosphono-amino acids
US5455279A (en) * 1991-04-19 1995-10-03 The Children's Medical Center Corporation Regimen method of mediating neuronal damage using nitroglycerine
AU2159792A (en) * 1991-06-05 1993-01-08 United States Of America, As Represented By The Secretary Of The Army, The A method of treating infectious encephalitis of viral or bacterial, or parasitic pathogenesis
US5206264A (en) * 1991-11-04 1993-04-27 Cypros Pharmaceutical Corporation Use of disulfiram to prevent cardiovascular damage
GB9206266D0 (en) * 1992-03-23 1992-05-06 Merck Sharp & Dohme Therapeutic agents
AU4540193A (en) * 1992-06-17 1994-01-04 United States Of America, Represented By The Secretary, Department Of Health And Human Services, The Method of treating and protecting against central nervous system ischemia, hypoxia, degeneration, and trauma with a 5-aminocarbonyl-sh-dibenzo{a,d}cyclohepten-5,10-imine
US5321012A (en) * 1993-01-28 1994-06-14 Virginia Commonwealth University Medical College Inhibiting the development of tolerance to and/or dependence on a narcotic addictive substance
USRE39300E1 (en) 1993-01-28 2006-09-19 Virginia Commonwealth University Medical College Of Virginia Inhibiting the development of tolerance to and/or dependence on an addictive substance
US5554620A (en) * 1993-09-14 1996-09-10 Sterling Winthrop Inc. Substituted 6,11-ethano-6,11-dihydrobenzo[b] quinolizinium salts and compositions and methods of use thereof
RU2106864C1 (ru) 1995-10-23 1998-03-20 Николай Серафимович Зефиров Средство для лечения болезни альцгеймера
US6025355A (en) * 1997-05-19 2000-02-15 Cambridge Neuroscience, Inc. Pharmaceutically active compounds and methods of use
US6242198B1 (en) 1996-07-25 2001-06-05 Cambridge Neuroscience, Inc. Methods of treatment of eye trauma and disorders
US6756389B2 (en) 1996-08-09 2004-06-29 Cambridge Neuroscience, Inc. Pharmaceutically active compounds and methods of use
US20060142186A1 (en) * 2004-12-23 2006-06-29 Voyager Pharmaceutical Corporation Leuprolide acetate and acetylcholinesterase inhibitors or NMDA receptor antagonists for the treatment of alzheimer's disease
KR100888379B1 (ko) * 2007-05-31 2009-03-13 한국과학기술연구원 성상교세포-뉴런 간 신호 전달 기작
KR101707907B1 (ko) * 2013-09-09 2017-02-17 제일모직 주식회사 화합물, 이를 포함하는 유기 광전자 소자 및 표시장치
WO2017216159A1 (en) * 2016-06-13 2017-12-21 Institut National De La Santé Et De La Recherche Médicale (Inserm) Novel dizocilpine derivatives as peripheral nmda receptor antagonists

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4064139A (en) * 1975-04-07 1977-12-20 Merck & Co., Inc. Substituted 9,10-dihydroanthracen-9,10-imines
US4374838A (en) * 1977-09-19 1983-02-22 Merck & Co., Inc. Dibenzo[a,d]cycloocten-5,12-(and 6,12)-imines
US4399141A (en) * 1977-09-19 1983-08-16 Merck & Co., Inc. 5-Alkyl or hydroxyalkyl substituted-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5,10-imines and anticonvulsant use thereof
NL7808848A (nl) 1977-09-19 1979-03-21 Merck & Co Inc Dibenzoa.dcyclo-octeen-5.12-(en 6.12)-iminen.
US4657899A (en) * 1986-04-09 1987-04-14 Nova Pharmaceutical Corporation Antagonists of specific excitatory amino acid neurotransmitter receptors

Also Published As

Publication number Publication date
US4888347A (en) 1989-12-19
CA1284952C (en) 1991-06-18
GB8600783D0 (en) 1986-02-19
EP0230370A3 (en) 1990-05-23
EP0230370B1 (en) 1992-08-12
DK170921B1 (da) 1996-03-18
EP0230370A2 (en) 1987-07-29
DK14587A (da) 1987-07-15
DE3780972T2 (de) 1993-03-04
DE3780972D1 (de) 1992-09-17
JPS62181216A (ja) 1987-08-08
JP2549643B2 (ja) 1996-10-30
IL81162A (en) 1990-12-23

Similar Documents

Publication Publication Date Title
DK14587D0 (da) Anvendelse af specifikke n-methyl-d-aspartat-receptorantagonister til undgaaelse af og behandling af neurodegeneration
FR2602142B1 (fr) Utilisation en therapeutique des antagonistes des recepteurs serotoninergiques 5ht3
BR8800329A (pt) Metodos de geracao de modulos objeto de programas
DK151589D0 (da) Ultrasonisk behandling af dyr
DK551187D0 (da) Terapeutisk praeparat og dettes fremstilling
DK279890A (da) Liposom-indkapslede vincaalkaloider og anvendelse heraf til fremstilling af et laegemiddel til bekaempelse af tumorer
IT1204984B (it) Procedimento e dispositivo per cordonare
DK134087A (da) Platformsforankring
DK329289A (da) Ny terapeutisk anvendelse af h2-receptorblokerende forbindelser
TR24926A (tr) Diflufenikan kullanan herbisidal usul
DK87888A (da) Terapeutisk anvendelse af tindijoddeuteroporfyrin
DK298187A (da) Applikator til behandling af laeber
IT8448001A1 (it) Forme galeniche di sulpiride utilizzabili per via orale e procedimento per produrle.
NO873512L (no) Human lav-affinitets fcepsilon-reseptor, isolering, rekombinant fremstilling og rensing av denne.
DK604887A (da) Forankringsorgan
DK95890D0 (da) Anvendelse af paf-antagonister til behandling af autoimmune sygdomme
DK615489D0 (da) Hidtil ukendt behandling
KR870011914U (ko) 착탈식 화운데이숀의 착설구조
DK185987A (da) Anvendelse af prostaglandiner
IT1191659B (it) Procedimento di trattamento dell'acqua
KR870000771U (ko) 수로 구조물의 긴결장치
KR880005395U (ko) 계단파를 이용한 아날로그-디지탈 변환기
KR880014410U (ko) 음향기기 세트의 결합 장치
ES292986Y (es) Mortero perfeccionado
SE8601388D0 (sv) Anordning for utnyttjande av vagenergi

Legal Events

Date Code Title Description
B1 Patent granted (law 1993)
PBP Patent lapsed